This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 33 open trials
MGUS research study
The aim of this study is to gain an understanding of the functional consequences of paraprotein production in monoclonal gammopathy of undetermined significance (MGUS) patients.
In most cases of MGUS patients do not experience symptoms. However, in a small number of patients there may be an interaction of the paraprotein with a molecule expressed by the body (self antigen) which can have effects on the normal function of this molecule and may cause disease.
Royal Berkshire Hospital, Reading;
Addenbrooke's Hospital, Cambridge;
Torbay Hospital, Torquay;
Heartlands Hospital, Birmingham;
St James' Hospital, Leeds;
Guy's Hospital, London;
Freeman Hospital, Newcastle;
City Hospital, Nottingham;
Rotherham General Hospital, Rotherham
Who can enter the study?:
Patients with a confirmed diagnosis of MGUS.
Patients taking part in this study will have a blood sample taken for analysis and will be asked to complete a lifestyle questionnaire.
Patients will be contacted 2 years after the blood sample is taken to enquire about their MGUS status and whether there has been any progression to myeloma.
(for Medical Professionals):
This is a research study to investigate the functional consequence of paraprotein production in MGUS patients.
For more information, click here